Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at HC Wainwright raised their Q3 2025 EPS estimates for Tarsus Pharmaceuticals in a report issued on Thursday, August 7th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.32) per share for the quarter, up from their prior forecast of ($0.35). HC Wainwright has a “Buy” rating and a $72.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($1.56) EPS, FY2026 earnings at ($2.15) EPS and FY2028 earnings at $0.30 EPS.

Several other analysts have also commented on TARS. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 22nd. The Goldman Sachs Group raised their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a “neutral” rating in a research report on Monday, May 5th. Guggenheim raised their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Finally, Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an “outperform” rating and a $75.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $66.67.

Tarsus Pharmaceuticals Stock Down 0.2%

NASDAQ:TARS opened at $47.85 on Monday. The firm has a market capitalization of $2.01 billion, a P/E ratio of -20.54 and a beta of 0.79. Tarsus Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $57.28. The company’s fifty day moving average price is $41.55 and its 200-day moving average price is $45.66. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). The company had revenue of $102.66 million during the quarter, compared to analysts’ expectations of $95.81 million. Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.

Institutional Trading of Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $44,000. Amalgamated Bank grew its stake in shares of Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock worth $65,000 after purchasing an additional 295 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock worth $66,000 after purchasing an additional 339 shares during the period. Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $166,000. Finally, AlphaQuest LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 1st quarter worth $189,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.